文献速递心力衰竭与心肌病冠心病血脂与心血管预防

能量剥夺信号紊乱在感知营养过剩时心脏和肾脏疾病发病机制中的作用

Role of Deranged Energy Deprivation Signaling in the Pathogenesis of Cardiac and Renal Disease in States of Perceived Nutrient Overabundance.
PubMed 文献 · Circulation · 2020-03-13

SGLT2抑制剂降低心衰和肾脏事件风险,但机制未明。其治疗特征为生酮和红细胞增多,反映诱导类 fasting 和类缺氧转录范式,激活SIRT1、AMPK和HIF-2α,增强自噬,减少细胞应激和钠内流,恢复线粒体稳态。2型糖尿病、肥胖、心衰和肾衰时细胞内糖脂中间产物积累被感知为能量过剩,下调这些信号,损害自噬,加速心肌病和肾病。SGLT2抑制剂逆转此适应不良信号。

要点

  • SGLT2抑制剂通过模拟 fasting 和缺氧状态,激活SIRT1、AMPK和HIF-2α。
  • 激活SIRT1和AMPK驱动生酮,HIF促进红细胞生成,增强自噬。
  • 这些机制减少细胞应激和钠内流,恢复线粒体稳态,解释心肾保护。

核心结论

  • SGLT2抑制剂通过诱导类 fasting 和类缺氧转录范式,激活SIRT1、AMPK和HIF-2α,增强自噬,减少细胞应激和钠内流,恢复线粒体稳态,从而发挥心肾保护作用。

主要发现

  • SGLT2抑制剂治疗的特征是生酮和红细胞增多,反映类 fasting 和类缺氧转录范式的诱导。
  • SIRT1激活驱动生酮,与AMPK协同抑制炎症小体激活,维持线粒体容量和稳定性。
  • HIFs促进氧输送(通过刺激促红细胞生成素和红细胞增多)并减少氧消耗。
  • SIRT1、AMPK和HIF-2α激活增强自噬,清除受损线粒体和过氧化物酶体。
  • SIRT1和AMPK作用于钠转运机制,降低细胞内钠浓度。

临床怎么用

  • SGLT2抑制剂的心肾保护作用可能与其诱导类 fasting 和类缺氧信号、增强自噬、减少细胞应激和钠内流有关,支持在相关疾病中使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sodium-glucose cotransporter 2 inhibitors reduce the risk of serious heart failure and adverse renal events, but the mechanisms that underlie this benefit are not understood. Treatment with SGLT2 inhibitors is distinguished by 2 intriguing features: ketogenesis and erythrocytosis. Both reflect the induction of a fasting-like and hypoxia-like transcriptional paradigm that is capable of restoring and maintaining cellular homeostasis and survival. In the face of perceived nutrient and oxygen deprivation, cells activate low-energy sensors, which include sirtuin-1 (SIRT1), AMP-activated protein kinase (AMPK), and hypoxia inducible factors (HIFs; especially HIF-2α); these enzymes and transcription factors are master regulators of hundreds of genes and proteins that maintain cellular homeostasis. The activation of SIRT1 (through its effects to promote gluconeogenesis and fatty acid oxidation) drives ketogenesis, and working in concert with AMPK, it can directly inhibit inflammasome activation and maintain mitochondrial capacity and stability. HIFs act to promote oxygen delivery (by stimulating erythropoietin and erythrocytosis) and decrease oxygen consumption. The activation of SIRT1, AMPK, and HIF-2α enhances autophagy, a lysosome-dependent degradative pathway that removes dangerous constituents, particularly damaged mitochondria and peroxisomes, which are major sources of oxidative stress and triggers of cellular dysfunction and death. SIRT1 and AMPK also act on sodium transport mechanisms to reduce intracellular sodium concentrations. It is interesting that type 2 diabetes mellitus, obesity, chronic heart failure, and chronic kidney failure are characterized by the accumulation of intracellular glucose and lipid intermediates that are perceived by cells as indicators of energy overabundance. The cells respond by downregulating SIRT1, AMPK, and HIF-2α, thus leading to an impairment of autophagic flux and acceleration of cardiomyopathy and nephropathy. SGLT2 inhibitors reverse this maladaptive signaling by triggering a state of fasting and hypoxia mimicry, which includes activation of SIRT1, AMPK, and HIF-2α, enhanced autophagic flux, reduced cellular stress, decreased sodium influx into cells, and restoration of mitochondrial homeostasis. This mechanistic framework clarifies the findings of large-scale randomized trials and the close association of ketogenesis and erythrocytosis with the cardioprotective and renoprotective benefits of these drugs.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Packer M. Role of Deranged Energy Deprivation Signaling in the Pathogenesis of Cardiac and Renal Disease in States of Perceived Nutrient Overabundance. Circulation. 2020. PMID: 32164457. doi:10.1161/CIRCULATIONAHA.119.045561

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。